Impact of BMI on response to Janus kinase inhibitors in rheumatoid arthritis: an individual patient data meta-analysis of randomised controlled trials [0.03%]
体重指数对风湿性关节炎Janus激酶抑制剂疗效影响的个体患者数据分析meta分析
Katie Bechman,Mark D Russell,Kathryn Biddle et al.
Katie Bechman et al.
Background: Obesity is common in patients with rheumatoid arthritis and is associated with poorer disease outcomes. We aimed to evaluate the association between BMI and clinical response to Januse kinase (JAK) inhibitors ...
BMI as a modifier of Janus kinase inhibitor response in rheumatoid arthritis [0.03%]
体重指数作为 janus 激酶抑制剂治疗类风湿性关节炎疗效的影响因素
Chary Lopez Pedrera,Carlos Perez Sanchez
Chary Lopez Pedrera
Naina McCann,Pratyasha Saha,Melissa Chowdhury et al.
Naina McCann et al.
The erosion of seronegative autoimmune diseases through the lens of autoantibodies [0.03%]
自身抗体视角下的自身免疫性疾病阴影范围的缩减
Carlo Selmi,Antonio Tonutti,Suraj Timilsina et al.
Carlo Selmi et al.
Autoantibodies are central to the diagnosis, classification, and stratification of many autoimmune diseases, particularly those characterised by B-cell activation and MHC class II associations. However, a substantial proportion of patients ...
Re-evaluating anti-AT1A1 for predicting fetal atrioventricular block in anti-SSA/Ro positive pregnancies [0.03%]
抗AT1A1抗体用于预测抗SSA/Ro阳性孕妇胎儿房室传导阻滞的临床价值再评价
Philip M Carlucci,Nalani Sachan,Diptendu Chatterjee et al.
Philip M Carlucci et al.
Beyond MRI positivity in axial spondyloarthritis: the ubiquity of bone marrow oedema and risk of overinterpretation [0.03%]
骶髂关节炎的MRI阳性之外：骨髓水肿的普遍性及过度解读的风险
Gaëlle Varkas,Victoria Navarro-Compán
Gaëlle Varkas
When and how chronicity develops in rheumatoid arthritis: towards a temporal and tissue-integrated perspective [0.03%]
论风湿性关节炎的慢性化发展及其时间与组织综合视角
Alper Cevirgel,Annette H M van der Helm-van Mil
Alper Cevirgel
Although the diagnosis of rheumatoid arthritis can usually be made once clinical arthritis appears, this moment does not represent the biological onset of disease. Rheumatoid arthritis develops over a period of years in preclinical phases t...
The end for avacopan [0.03%]
阿瓦西普的终结？
The Lancet Rheumatology
The Lancet Rheumatology
Gwenny M Verstappen,Zana Brkic
Gwenny M Verstappen